Table 1.
Leukemia latency and penetrance in secondary hosts.
| 1° Hosts | Clone | 2° Hosts | Transplanted cell number | Dead | Survival (d) | 1° Hosts | Clone | 2° Hosts | Transplanted cell number | Dead | Survival (d) |
| WT | I-18 | Rag2−/−gc−/− | 50,000 | 1/3 | 64, >70, >70 | Rag2−/−gc−/− | I-7 | Rag2−/−gc−/− | 50,000 | 0/3 | >70, >70, >70 |
| 100,000 | 1/3 | 68, >70, >70 | 100,000 | 0/3 | >70, >70, >70 | ||||||
| Rag2−/− | 50,000 | 2/3 | 48, 68, >70 | Rag2−/− | 50,000 | 0/3 | >70, >70, >70 | ||||
| 100,000 | 0/3 | >70, >70, >70 | 100,000 | 0/3 | >70, >70, >70 | ||||||
| WT | 300,000 | 0/3 | >70, >70, >70 | WT | 300,000 | 0/3 | >70, >70, >70 | ||||
| I-19 | Rag2−/−gc−/− | 50,000 | 3/3 | 35, 46, 49 | II-1 | Rag2−/−gc−/− | 50,000 | 3/3 | 26, 27, 28 | ||
| 100,000 | 3/3 | 32, 33, 49 | 100,000 | 3/3 | 26, 28, 28 | ||||||
| Rag2−/− | 50,000 | 4/4 | 38, 53, 63, 68 | Rag2−/− | 50,000 | 4/4 | 29, 29, 30, 31 | ||||
| 100,000 | 3/3 | 38, 38, 38 | 100,000 | 3/3 | 26, 28, 28 | ||||||
| WT | 50,000 | 0/5 | >70, >70, >70, >70, >70 | WT | 50,000 | 2/3 | 51, 67, >70 | ||||
| 100,000 | 0/5 | >70, >70, >70, >70, >70 | 100,000 | 2/3 | 42, 46, >70 | ||||||
| 300,000 | 2/5 | 32, 34, >70, >70, >70 | 300,000 | 3/3 | 25, 26, 39 | ||||||
| II-16 | Rag2−/−gc−/− | 50,000 | 3/3 | 22, 31, 31 | II-2 | Rag2−/−gc−/− | 50,000 | 4/4 | 33, 33, 34, 34 | ||
| 100,000 | 4/4 | 23, 24, 24, 30 | 100,000 | 4/4 | 28, 30, 31, 32 | ||||||
| Rag2−/− | 50,000 | 4/4 | 29, 35, 35, 35 | Rag2−/− | 50,000 | 3/3 | 28, 29, 29 | ||||
| 100,000 | 3/3 | 30, 32, 32 | 100,000 | 4/4 | 28, 31, 31, 33 | ||||||
| WT | 50,000 | 0/3 | >70, >70, >70 | WT | 50,000 | 3/3 | 29, 31, 41 | ||||
| 100,000 | 2/4 | 30, 38, >70, >70 | 100,000 | 4/4 | 28, 29, 32, 35 | ||||||
| 300,000 | 3/4 | 27, 27, 48, >70 | 300,000 | 4/5 | 28, 30, 30, 35, >70 | ||||||
| II-18 | Rag2−/−gc−/− | 50,000 | 3/3 | 43, 52, 55 | II-6 | Rag2−/−gc−/− | 50,000 | 3/3 | 36, 37, 37 | ||
| 100,000 | 3/3 | 43, 54, 55 | 100,000 | 3/3 | 30, 34, 36 | ||||||
| Rag2−/− | 50,000 | 3/3 | 44, 64, 64 | Rag2−/− | 50,000 | 4/4 | 38, 43, 43, 43 | ||||
| 100,000 | 3/3 | 51, 57, 59 | 100,000 | 3/3 | 42, 45, 46 | ||||||
| WT | 50,000 | 0/3 | >70, >70, >70 | WT | 50,000 | 0/2 | >70, >70 | ||||
| 100,000 | 1/3 | 63, >70, >70 | 100,000 | 0/3 | >70, >70, >70 | ||||||
| 300,000 | 2/3 | 45, 57, >70 | 300,000 | 2/2 | 35, 35 | ||||||
| III-17 | Rag2−/−gc−/− | 50,000 | 3/3 | 25, 25, 25 | III-3 | Rag2−/−gc−/− | 50,000 | 4/4 | 25, 25, 25, 25 | ||
| 100,000 | 3/3 | 21, 22, 22 | 100,000 | 3/3 | 21, 25, 28 | ||||||
| Rag2−/− | 50,000 | 3/3 | 24, 25, 25 | Rag2−/− | 50,000 | 3/3 | 25, 25, 25 | ||||
| 100,000 | 3/3 | 25, 25, 26 | 100,000 | 3/3 | 24, 25, 28 | ||||||
| WT | 50,000 | 2/3 | 24, 28, >70 | WT | 50,000 | 3/3 | 27, 27, 46 | ||||
| 100,000 | 3/3 | 28, 35, 36 | 100,000 | 2/3 | 27, 28, >70 | ||||||
| 300,000 | 4/6 | 19, 30, 30, 40, >70, >70 | 300,000 | 6/6 | 23, 26, 27, 31, 32, 34 | ||||||
| III-19 | Rag2−/−gc−/− | 50,000 | 4/4 | 20, 22, 22, 23 | III-6 | Rag2−/−gc−/− | 50,000 | 3/3 | 44, 52, 60 | ||
| 100,000 | 4/4 | 22, 22, 22, 22 | 100,000 | 3/3 | 32, 32, 46 | ||||||
| Rag2−/− | 50,000 | 3/3 | 23, 23, 23 | Rag2−/− | 50,000 | 4/4 | 37, 51, 63, 65 | ||||
| 100,000 | 4/4 | 20, 20, 24, 24 | 100,000 | 4/4 | 33, 38, 48, 48 | ||||||
| WT | 50,000 | 3/3 | 20, 22, 25 | WT | 50,000 | 2/3 | 54, 65, >70 | ||||
| 100,000 | 3/3 | 20, 20, 21 | 100,000 | 4/4 | 48, 50, 50, 51 | ||||||
| 300,000 | 5/5 | 20, 20, 21, 23, 25 | 300,000 | 4/6 | 36, 44, 57, 59, >70, >70 |
50,000, 100,000, or 300,000 primary leukemic cells from WT or Rag2−/−gc−/− hosts (Fig 2A) were transplanted to secondary WT or immunodeficient environments and monitored over 70 d. Depicted is the origin of leukemia, type of secondary host, the assessed cell numbers, the incidence of mortality, and the time until death. Bold entries indicate groups with surviving mice.